All News

Article

Outcomes Switching to Monotherapy: SEAM-RA Trial

Eric Dein, MD

Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety. 

Adam Kilian MD Tweet
KilianMD
Pearls from @anisha_dua for differentiating atherosclerosis vs. vasculitis inflammation on imaging: 1. Look at the Axillary arteries - they tend to be less likely affected by atherosclerosis 2. Vasculitic lesions tend to be concentric & longer/continuous #ACR20 #RheumTwitter
Jilaine Bolek Berquist Tweet
BolekBerqui
Evidence-Based Guidance for Optimizing Gout #ACR20 Reminding us of cardioprotective effect of anti-inflammatory gout management with colchicine. https://t.co/TmsrRd2vFD
Puja Mehta 🧩 Tweet
DrPujaMehta1
@AngusWorthing @r_burmester Is the ‘thieves’ market’ session named after our history of stealing drugs? 😱 😂
Angus Worthing MD Tweet
AngusWorthing
Today's #ACR20 lecture @r_burmester shows the biologic revolution was a result of serendipity -- this will spark the long-awaited new & improved name of our profession: serendipitology! Hi I'm Dr. Worthing I'm a Serendipitologist. I use drugs intended for infections, cancer etc.! https://t.co/buDqwAVK9u
Mohammad A. Ursani MD, RhMSUS Tweet
DrMAUrsani
Dr Joan Merrill presents a phase 2 trial use of Iberdomide in patients with #SLE -Novel MOA —> blocks TF Ailos and Ikaros Conclusion -Primary end point was met at week 24 -Effects greater in Aiolos high/Type 2 IFN high -Iverdomdie was tolerated well #Lupus #ACR20 #ACRambassador https://t.co/zpQR9ceV7p
E. Sloan Tweet
esloanmd
Nice succinct review of recent DOAC studies in #APS by Dr. Ortel. Recommends avoiding DOACs in triple positive pts #antiphospholipid #ACR20 https://t.co/Hc6ye3mvTg
Mohammad A. Ursani MD, RhMSUS Tweet
DrMAUrsani
Dr Richard Furie-> Obinutuzumab for proliferative #lupus nephritis -Compared to rituximab, has more B-cell depletion in tissue and #SLE patients -Meaningful benefits over SOC alone on renal response through week 104. -Phase 3 REGENCY pending. #ACR20 #ACRambassador #Rheumatology https://t.co/aPi1yueAiV
Richard Conway Tweet
RichardPAConway

After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow

Mrinalini Dey Tweet
DrMiniDey
Thanks @EBRheum for a great rundown of how to keep up with the #rheumatology literature- particularly liked the reminder to use tech & @Twitter as well as reading. "#RheumTwitter is fun, it's collaborative, it's full of doughnuts." Proud to be a rheum trainee!😄 #ACR20 @RheumNow https://t.co/V1zaUD1KCJ
David Liew Tweet
drdavidliew
Should ARBs be adjunct Rx in GCA? Plausible target: - previous pharmacoepi - ATII expressed in GCA inflamm lesions - ATII induced pro-inflamm in PBMC/co-cultured VSMC - steroids modulate ATII expression in GCA TA ex vivo Maybe worth testing? Cid et al #ACR20 ABST0510 @RheumNow https://t.co/mNNzZVYe7g
Olga Petryna Tweet
DrPetryna
@RheumNow #acr20 abs0622 infection induced MPO anca vasc: most common triggers viruses(35.2%), mycobacterial (29.4%)& bacterial inf (29.4%). Onset 3 mo post inf. (70.5%) renal involvement, w/ biopsy-proven GN in 53%. 17.6%died. Rx steroids+abx, CYC in 47%.
Robert B Chao, MD Tweet
doctorRBC
EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts 1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC 2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC @RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc
Olga Petryna Tweet
DrPetryna
@RheumNow #acr20 abs0665 claim based database stdy of pegloticase/immunomodulation coadministration trends: use of co-immunomodulation ⬆️ from 1.2%-3.9% 2015- 2018 to 15.0% in 2019. 86%start immunomodulator within 30 days of first peg infusion. MTX most commonly used
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×